SCIENTIFIC PROGRAMME
SESSION I
HOW I TREAT
SMOLDERING MYELOMA
(SMM)
SESSION II
HOW I TREAT NEWLY
DIAGNOSED MULTIPLE
MYELOMA
SESSION III
FROM RISK
STRATIFICATION TO
RISK-BASED THERAPY?
DEBATE 1
SHOULD WE USE MRD
TESTING TO DETERMINE
THERAPY IN MULTIPLE
MYELOMA?
DEBATE 2
IS THERE A FUTURE ROLE
OF AUTOLOGOUS STEM
CELL TRANSPLANTATION?
SESSION IV
HOW I TREAT RELAPSED
MULTIPLE MYELOMA
DEBATE 3
SHOULD EVERY PATIENT
RECEIVE DARATUMUMAB
IN FIRST LINE?
ROUNDTABLE
MULTIPLE MYELOMA
FROM THE PERSPECTIVE
OF FDA/EMEA AND
FOUNDATIONS
SESSION V
YOU CAN’T BE IMMUNE
FOR IMMUNE THERAPY
ANYMORE
SESSION VI
OTHER PLASMA CELL
DYSCRASIAS
KEYNOTE LECTURES
THE FUTURE OF
MULTIPLE MYELOMA
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
ABSTRACTS SELECTED
AS POSTERS
DISCLOSURES
interventions and monitoring including through novel wearables, relaxation of regulations to accelerate
drug development and diagnostics such as the ones around Laboratory Derived Tests (LDTs) in the US.
COVID-19 has also emphasized the disparities that exist in cancer care in general and myeloma in
particular, and served as a catalyst for serious efforts being put into developing more inclusive trials for
under-represented MM populations (10). It is certain that some of these innovations are here to stay and
will impact for the better MM drug development in 2021 and beyond.
References
1. Shah UA and Mailankody S. Emerging immunotherapies in multiple myeloma. BMJ 2020 370:m3176.
doi: 10.1136/bmj.m3176.
2. Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R et al., Early relapse after autologous
hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but
outcomes have improved over time. Leukemia 2018 32(4):986-995.
3. Auclair D, Lonial S, Anderson KC, Kumar SK. Precision medicine in multiple myeloma: are we there yet?
Expert Review of Precision Medicine and Drug Development 2019; 4(2): 51-53.
4. Mateos M-V, Kumar S, Dimopoulos MA, González-Calle V, Kastritis E, Hajek R et al. International
Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood
Cancer J 2020 Oct 16; 10(10):102.
5. Bustoros M, Sklavenitis-Pistofidis R, Park J, Redd R, Zhitomirsky B, Dunford AJ et al. Genomic Profiling
of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol
2020 Jul 20; 38(21):2380-2389.
6. Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ et al., Randomized Trial of Lenalidomide
Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol 2020 Apr 10; 38(11):1126-1137.
7. Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C et al. Venetoclax or placebo in
combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple
myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol.2020 Dec
21(12):1630-1642.
8. Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M et al. A large meta-analysis
establishes the role of MRD negativity in long-term survival outcomes in patients with multiple
myeloma. Blood Adv (2020) 4 (23): 5988–5999.
9. Samur MK, Fulciniti M, Samur AA, Bazarbachi AH, Tai Y-T, Prabhala R, et al. Biallelic loss of BCMA as a
resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun 2021
Feb 8;12(1):868.
10. Gormley N, Fashoyin-Aje L, Locke T, Unger JM, Little RF, Nooka A, et al. Recommendations on
Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step toward Achieving Equity in
Healthcare. Blood Cancer Discov 2021; 2:119–24.